GLENMARK

Short Story on Recent Triumphs & Key Challenges.

: On the Move!💊🚀 🔹 March 12, 2025: Launched Empagliflozin (Glempa) in India for diabetes. 🔹 March 10, 2025: Introduced Polyethylene Glycol 3350 in the U.S. market. 🔹 March 5, 2025: Recalled 1.5M bottles of ADHD drug Atomoxetine in the U.S. over impurity concerns. 🔹 February 14, 2025: Reported 35.1% YoY revenue growth, 17.7% EBITDA margin in Q3 FY25. 🔹 January 20, 2025: Laid off 150 employees across India for restructuring. 🔹 December 5, 2024: Settled $7M U.S. antitrust lawsuit without admitting wrongdoing. 🔹 November 20, 2024: Aurangabad facility cleared USFDA inspection (zero observations). 📊 Stock Insight: Glenmark’s beta is 0.9-1.09, indicating moderate volatility. ⏳ Future Outlook: 🔸 Next USFDA check remains unknown, but Glenmark continues crossing key milestones. 🔸 Global tariffs & macro risks could impact performance. Investors, stay sharp! Share your views in Comment!